Physician

Chirag M Shah, MD

According to 2025 Medicare claims, Chirag Shah, MD (NPI: 1053345629) practices hematology/oncology in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Ocean, NJ. This provider's primary affiliated billing organization is ADVANCED CANCER CARE OF NEW JERSEY,PC (NPI: 1255529244; TIN: 202814225) and primary practice location at 08753-2989.

Shah's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 952 traditional Medicare patients, billed 358,974 HCPCS/CPT codes, and received $4,245,858 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 1,525 prescription claims across 291 beneficiaries totaling $8,670,441 in drug costs, led by Ibrance (Palbociclib). DME data shows 103 claims. Open Payments data shows 38 records totaling $1,043. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $1,201,171 to $8,670,441. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $6,654 to $4,568.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	655	165,988	$1,948,447
2016	642	166,356	$1,940,536
2017	958	392,441	$4,652,124
2018	916	424,031	$6,037,448
2019	932	387,947	$5,289,388
2020	861	337,602	$4,702,383
2021	821	353,649	$5,153,240
2022	849	301,711	$3,937,601
2023	922	381,459	$4,656,444
2024	952	358,974	$4,245,858

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	122	679	$1,201,171
2016	144	794	$1,659,127
2017	266	1,507	$3,224,713
2018	274	1,450	$3,733,123
2019	331	1,551	$4,782,279
2020	326	1,668	$6,202,336
2021	314	1,526	$5,872,047
2022	297	1,662	$6,329,788
2023	267	1,365	$7,710,059
2024	291	1,525	$8,670,441

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	177	$49,024
2016	N/R	158	$21,323
2017	N/R	167	$19,681
2018	64	456	$25,547
2019	60	484	$36,866
2020	48	407	$25,472
2021	N/R	300	$10,509
2022	N/R	123	$3,263
2023	N/R	308	$13,886
2024	N/R	103	$5,041

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	213	281	$116
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	531	1,255	$109
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	427	733	$74
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	247	870	$70
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	104	308	$44

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	78	2,184	$1,216,518
Erleada	Apalutamide	76	2,350	$1,099,085
Calquence	Acalabrutinib Maleate	56	1,680	$754,727
Tagrisso	Osimertinib Mesylate	35	1,050	$577,439
Jakafi	Ruxolitinib Phosphate	31	930	$540,008

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0781	Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient	Y	N/R	14	$2,808
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	29	$1,018
J9190	Injection, fluorouracil, 500 mg	N	N/R	31	$677
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	29	$537

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	38	$1,043	Regeneron Healthcare Solutions, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Chirag M. Shah, MD?

Tedicare shows public-source Medicare data for Chirag M. Shah, MD (NPI 1053345629), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Chirag M. Shah, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Chirag M. Shah, MD?

Chirag M. Shah, MD is linked to ADVANCED CANCER CARE OF NEW JERSEY,PC (billing NPI 1255529244) in the available physician profile data.

Does Chirag M. Shah, MD have Open Payments data?

Chirag M. Shah, MD has 38 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.